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ABSTRACT
Background. Clostridioides difficile infection (CDI) is the most common cause of
hospital-acquired diarrhea. There is little available data regarding risk factors of CDI
for patients who undergo cardiac surgery. The study evaluated the course of CDI in
patients after cardiac surgery.
Methods. Of 6,198 patients studied, 70 (1.1%) developed CDI. The control group
consisted of 73 patients in whom CDI was excluded. Perioperative data and clinical
outcomes were analyzed.
Results. Patients with CDI were significantly older in comparison to the control group
(median age 73.0 vs 67.0, P = 0.005) and more frequently received proton pump
inhibitors, statins, β-blockers and acetylsalicylic acid before surgery (P = 0.008,P =
0.012,P = 0.004, and P = 0.001, respectively). In addition, the presence of atheroscle-
rosis, coronary disease and history of malignant neoplasms correlated positively with
the development of CDI (P = 0.012,P = 0.036 and P = 0.05, respectively). There were
no differences in the type or timing of surgery, aortic cross-clamp and cardiopulmonary
bypass time, volume of postoperative drainage and administration of blood products
between the studied groups. Relapse was more common among overweight patients
with high postoperative plasma glucose or patients with higher C-reactive protein
during the first episode of CDI, as well as those with a history of coronary disease
or diabetes mellitus (P = 0.005, P = 0.030,P = 0.009,P = 0.049, and P = 0.025,
respectively). Fifteen patients died (21.4%) from the CDI group and 7 (9.6%) from
the control group (P = 0.050). Emergent procedures, prolonged stay in the intensive
care unit, longer mechanical ventilation and high white blood cell count during the
diarrhea were associated with higher mortality among patients with CDI (P = 0.05,P =
0.041,P = 0.004 and P = 0.007, respectively).
Conclusions. The study did not reveal any specific cardiac surgery-related risk factors
for development of CDI.
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INTRODUCTION
Clostridioides difficile (CD) is widely spread in the human environment and present
in about 7–18% of the adult population (Donskey, Kundrapu & Deshpande, 2015). CD
infection (CDI) is the most common cause of hospital-acquired diarrhea and may follow
a severe course with many complications, which can include fatal colitis (Cunha, 1998;
Ricciardi et al., 2007). Despite increased efforts to prevent this infection, the incidence
and severity of nosocomial CDI has continued to grow worldwide (Ricciardi et al., 2007;
Clements et al., 2010).
Known risk factors for CDI include advanced age, female gender, use of broad-
spectrum antibiotics, use of proton pump inhibitors (PPI), chronic comorbidities,
immunocompromised states and prolonged, multiple hospital stays (McFarland, Surawicz
& Stamm, 1990; Eze et al., 2017; De Roo & Regenbogen, 2020; Furuya-Kanamori et al.,
2015a). Patients who undergo surgery present additional risks for CDI associated with
catheter-related infections, prolonged mechanical ventilation, extensive blood product
usage, indwelling catheter drainage and open cavities (Gelijns et al., 2014).
There is little available data regarding risk factors for CDI among patients who undergo
cardiac surgery. There have only been a few reports investigating the risk of CDI in patients
after heart procedures (Gelijns et al., 2014; Vondran et al., 2018; Flagg et al., 2014; Kirkwood
et al., 2018). This prompted us to evaluate the prevalence of hospital-acquired CDI after
cardiac surgery, identify patient characteristics and detect risk factors for CDI. Moreover
we assessed the course of the disease and final outcomes for this group of patients.
MATERIALS & METHODS
Patients
Between January 2014 and December 2016, a total of 6,198 adult patients underwent
cardiac surgery in our hospital. Seventy of the patients were diagnosed with CDI. The
control group was comprised of 73 patients for whom CDI had been excluded and this
group was matched to the group of CDI patients by the date of surgery.
Demographics, comorbidities, type and timing of cardiac surgery, operative
characteristics, perioperative antibiotic use, exposure to known risk factors for CDI and
in-hospital mortality were collected retrospectively. Additionally, length of hospitalization
until the onset of diarrhea, severity and recurrence of the disease, methods of treatment
and seasonal distribution of CDI were obtained.
CDI was suspected in each patient who experienced diarrhea (defined as the passage of
three ormore unformed stools per day). CDIwas defined as a combination of symptoms and
signs of the disease and confirmed by microbiological evidence of toxin-producing CD in
the patients’ stools (Debast, Bauer & Kuijper, 2014). Stool samples were analyzed using the
rapid enzyme immunoassays test, C. Diff Quik Chek Complete test (Techlab, Orlando,
USA).
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Non-severe CDI was defined by a white blood cell (WBC) count of ≤ 15,000 cells/mL
and a serum creatinine level < 1.5 mg/dL. Severe CDI was specified by a WBC count of
≥ 15,000 cells/mL or a serum creatinine level >1.5 mg/dL. Criteria for fulminant CDI
included occurrence of hypotension or shock, ileus or megacolon (McDonald et al., 2018).
The treatment of CDI was consistent with the 2010 recommendations (Cohen et al.,
2010). Metronidazole was the drug of choice for an initial episode of non-severe CDI and
vancomycin was the drug of choice for an initial episode of severe CDI. Combination
therapy with oral or rectal vancomycin and intravenously administered metronidazole was
the regimen of choice for the treatment of severe, complicated or fulminant CDI.
Recurrence of the disease was identified as a relapse within 8 weeks after the onset of
a previous episode (Debast, Bauer & Kuijper, 2014). Stress hyperglycemia was defined as
one or more blood sugar measurements > 180 mg/dL during the first postoperative 24 h
(Gelijns et al., 2014). In-hospital mortality was specified as death occurring during the same
hospitalization stay as the cardiac surgery.
Each patient received periprocedural antimicrobial prophylaxis (most often the first
generation of cephalosporin). Routine laboratory variables were determined using standard
laboratory techniques. Study protocol was approved by the local Research Ethics Committee
(Andrzej Frycz Modrzewski Krakow University, Krakow, Poland 10/2019). Verbal consent
of patients was acquired.
Statistical analysis
Descriptive statistics were described as numbers and percentages for categorical variables.
Continuous variables were presented as mean (± standard deviation) or median and
quartiles, as appropriate. Normality was assessed using the Shapiro–Wilk test. Equality
of variances was assessed using Levene’s test. Differences between groups were compared
using the Student’s or Welch’s t -test depending on the equality of variances for normal
distributed variables. The Mann–Whitney U test was used for non-normal distributed
continuous variables. Nominal variables were compared by the Pearson’s chi-square test
or Fisher’s exact test if 20% of cells had an expected count of less than 5. Significance was
accepted at P≤0.05. Statistical analyses were performed with JMP R©, Version 14.2.0 (SAS
Institute INC., Cary, NC, USA) and using R, Version 3.4.1 (R Core Team. R: A language and




Of the 6,198 patients, 70 (1.1%) developed CDI. Patients with CDI were significantly older
in comparison to the control group (median age 73.0 vs 67.0, P = 0.005). There was no
correlation between gender and incidence of CDI (P = 0.595). The European System for
CardiacOperative Risk Evaluation (EuroSCORE) valueswere higher in patientswithCDI (P
< 0.001). Patients with CDI more often received PPI, statins, β-blockers and acetylsalicylic
acid before surgery (P = 0.008, P = 0.012, P = 0.004, and P = 0.001, respectively). In
addition, the presence of atherosclerosis, coronary disease, and history of malignant
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neoplasms correlated positively with the development of CDI (P = 0.012, P = 0.036 and
P = 0.05, respectively). Patients in the CDI group were hospitalized more often during the
six months prior to the surgery (P = 0.001). Mean preoperative hospitalization time in the
cardiac surgery ward was 1.5 ± 0.2 days. Other baseline variables were comparable among
groups (Table 1).
Perioperative characteristics
The most common surgical procedures performed before CDI were valvular heart surgery
and coronary artery bypass grafting (41.4% and 35.7%, respectively). There were no
differences between the studied groups as far as the type or timing of surgery, aortic cross-
clamp and cardiopulmonary bypass time, volume of postoperative drainage, administration
of blood products, value of postoperative ejection fraction and frequency of reoperations.
Patients with CDI more frequently received additional antibiotics (P = 0.014). During the
early postoperative course patients with CDI had a significantly higher glucose level and
were exposed more frequently to stress hyperglycemia (P < 0.001 for both comparisons).
During the preoperative period, as well as after surgery, patients with CDI had a significantly
lower WBC count (P = 0.007 for both comparisons). Other intra- and postoperative
variables were similar in both groups (Table 2).
Course of Clostridioides difficile infection
The type of antibiotic therapy used before the first episode of CDI, median times of the
disease diagnosis and severity of the infection are shown in Table 3. Five patients in whom
fulminant CDI developed, underwent emergency laparotomy and two patients died due to
extensive multiple organ failure.
All patients with CDI were treated with oral metronidazole, oral vancomycin or both
(intravenous metronidazole with oral vancomycin). Fidaxomicin was not used in our
department during the study period (Table 3). Two patients underwent a fecal microbiota
transplant during recurrence of the disease.
Although baseline and early postoperative WBC count were significantly lower in
patients with CDI, during the course of the disease, WBC count was similar among
analyzed groups (P = 0.139). In contrast, C-reactive protein (CRP) was higher in the CDI
group during this period (P < 0.001).
There were no differences in the incidence rate of CDI between the analyzed years
although a seasonal pattern was observed. Most cases occurred in March (n= 14, 20%)
and the least number of cases were found in January (n= 2, 3%), (P = 0.038 between
March and rest of the months) (Fig. 1).
In 9 patients (12.9%) CDI recurred during hospitalization. Mean time of relapse was
27.7 ± 11.8 days after the first episode of the disease. Recurrent CDI was more common
in overweight patients having high plasma glucose just after surgery or a higher CRP
level during the first episode of the disease as well as for those with a history of coronary
disease or diabetes mellitus (P = 0.005, P = 0.030, P = 0.009, P = 0.049, and P = 0.025,
respectively), (Table 4).
Fifteen patients (21.4%) died from the CDI group and 7 (9.6%) from the control
group (P = 0.050). The median number of days between CDI diagnosis and death was
Rzucidło-Hymczak et al. (2020), PeerJ, DOI 10.7717/peerj.9972 4/16






Age (years) 73.0 [64.0–78.0] 67.0 [58.0–74.0] 0.005 (M)
Male, n(%) 45 (64.3) 51 (69.9) 0.595
BMI (kg/m2) 28.0 [24.4–32.0] 27.2 [24.4–31.3] 0.557
BMI > 25 kg/m2, n(%) 50 (71.4) 47 (64.4) 0.431
Logistic EuroSCORE (points) 6.0 [5.0–9.0] 5.0 [4.0–7.0] <0.001 (M)
LVEF (%) 55.0 [41.2–60.0] 50.0 [40.0–60.0] 0.144
LVEF< 40%, n(%) 14 (20.0) 14 (19.2) 0.901
Hospitalization < 6 month before the surgery, n(%) 62 (88.6) 46 (63.0) 0.001 (C)
Comorbidities, n(%)
Atherosclerosis 33 (47.1) 21 (28.8) 0.036 (C)
Dyslipidemia 57 (81.4) 50 (68.5) 0.112
Coronary disease 49 (70.0) 35 (47.9) 0.012 (C)
Previous myocardial infarction 21 (30.0) 18 (24.7) 0.597
Atrial fibrillation 29 (41.4) 22 (30.1) 0.217
Diabetes mellitus 28 (40.0) 19 (26.0) 0.110
History of malignant neoplasms 9 (12.9) 2 (2.7) 0.050
Chronic kidney disease 20 (28.6) 14 (19.2) 0.262
Thyroid disease 16 (22.9) 12 (16.4) 0.450
Peptic ulcer disease 15 (21.4) 7 (9.6) 0.084
COPD 7 (10.0) 8 (11.0) 1.000
Medicines, n(%)
Statins 59 (84.3) 47 (64.4) 0.012 (C)
Acetylsalicylic acid 60 (85.7) 44 (60.3) 0.001 (C)
Beta blockers 60 (85.7) 46 (63.0) 0.004 (C)
ACE inhibitors 42 (60.0) 32 (43.8) 0.077
Insulin 18 (25.7) 10 (13.7) 0.110
PPI 61 (87.1) 49 (67.1) 0.008 (C)
Corticosteroids 4 (5.7) 4 (5.5) 1.000
Laboratory parameters
WBC (×103/µL) 7.4 [6.3–8.8] 8.2 [6.7–11.0] 0.007 (M)
WBC> 10,000 µL, n(%) 8 (11.4) 24 (32.9) 0.002 (C)
Platelets (×103/µL) 200.5 [159.2–261.5] 216.0 [169.0–266.0] 0.241
Platelets< 140,000 µL, n(%) 9 (12.9) 5 (6.8) 0.227
Hematocrit (%) 39.3 [35.6–42.7] 38.5 [34.0–41.6] 0.368
Hemoglobin (g/dL) 13.0 [11.9–14.2] 12.5 [11.0–14.0] 0.241
Hemoglobin< 10 g/dL, n(%) 9 (12.9) 12 (16.4) 0.545
RBC (×106 /µL) 4.4 [4.0–4.9] 4.4 [3.8–4.7] 0.283
Creatinine (µmol/L) 91.5 [82.2–115.8] 99.0 [77.0–115.0] 0.928
Creatinine> 100 µmol/L, n(%) 26 (37.1) 32 (43.8) 0.415
Notes.
Continuous variables are presented as median (interquartile range). Categorical variables are presented as number (percentage).
(C), Pearson’s chi-square test; (M), Mann–Whitney U test; ACE, angiotensin-converting enzyme; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
LVEF, left ventricular ejection fraction; PPI, proton pump inhibitors; RBC, red blood cells; WBC, white blood cells.
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Type of surgery, n(%) 0.239
CABG 25 (35.7) 21 (28.8) 0.374
VHS 29 (41.4) 34 (46.6) 0.535
CABG+VHS 7 (10.0) 6 (8.2) 0.711
Aortic surgery 6 (8.6) 12 (16.4) 0.156
CABG+aortic surgery 3 (4.3) 0 (0.0) 0.115
Reoperation, n(%) 5 (7.1) 7 (9.6) 0.821
Timing of surgery, n(%) 0.217
Elective 41 (58.6) 51 (69.9)
Emergent 29 (41.4) 22 (30.1)
Additional antibiotic, n(%) 46 (65.7) 32 (43.8) 0.014 (C)
LVEF after surgery (%) 45.0 [40.0-50.0] 45.0 [35.0-55.0] 0.839
LVEF< 30%, n(%) 5 (7.1) 10 (13.7) 0.201
Aortic cross-clamp time (min) 65.0 [36.2–89.5] 69.0 [49.0–92.0] 0.517
CPB time (min) 104.5 [74.0–154.5] 125.0 [85.0–165.0] 0.156
Postoperative drainage (ml/first 24 h) 530.0 [332.5–940.0] 520.0 [380.0–810.0] 0.981
Postoperative drainage> 1,000 ml/first 24 h, n(%) 17 (24.3) 12 (16.4) 0.243
Inotropic agents, n(%) 48 (68.6) 53 (72.6) 0.730
IABP after surgery, n(%) 2 (2.9) 2 (2.7) 1.000
Accompanying infections, n(%)
Wound infection 13 (18.6) 13 (17.8) 1.000
VAC therapy 11 (15.7) 5 (6.8) 0.157
Positive blood cultures 10 (14.3) 15 (20.5) 0.444
Transfusion, n(%)
Red blood cells ≥2 units 43 (61.4) 41 (56.2) 0.639
Plasma ≥2 units 23 (32.9) 23 (31.5) 1.000
Platelets ≥1 unit 21 (30.0) 24 (32.9) 0.849
Laboratory parameters
WBC (×103/µL) 9.7 [7.0–13.6] 12.9 [9.3–15.6] 0.007 (M)
WBC> 13,000 µL, n(%) 21 (30.0) 36 (49.3) 0.018 (C)
Platelets (×103/µL) 122.5 [86.5–154.0] 130.0 [93.0–168.0] 0.261
Platelets< 100,000 µL, n(%) 23 (32.9) 22 (30.1) 0.726
Hematocrit (%) 28.6 [26.8–30.9] 29.4 [27.0–32.4] 0.104
Hemoglobin (g/dL) 9.6 [8.8–10.5] 9.8 [9.0–10.7] 0.229
Hemoglobin< 8.0 g/dL, n(%) 9 (12.9) 6 (8.2) 0.366
RBC (×106 /µL) 3.2 [3.0–3.4] 3.3 [3.0–3.5] 0.118
Plasma glucose (mmol/L) 11.5 [9.7–12.8] 9.2 [8.1–10.7] <0.001 (M)
Stress hyperglycemia, n(%) 48 (68.6) 24 (32.9) <0.001 (C)
In-hospital death, n(%) 15 (21.4) 7 (9.6) 0.050 (C)
Notes.
Continuous variables are presented as median (interquartile range). Categorical variables are presented as number (percentage).
(C), Pearson’s chi-square test; (M), Mann–Whitney U test; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; IABP, intra-aortic balloon pump;
LVEF, left ventricular ejection fraction; RBC, red blood cells; VHS, valvular heart surgery; VAC, Vacuum-assisted closure; WBC, white blood cells.
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Table 3 Course of Clostridioides difficile infection general data.
Variable Patients with CDI
(n= 70)























Times of the CDI diagnosis (days)
Between hospital admission and CDI diagnosis 12.0 [6.2–30.5]
Between the surgery and CDI diagnosis 9.0 [5.0–27.2]
Length of ICU stay before the CDI diagnosis 4.0 [2.0–7.0]
Assisted ventilation before the CDI diagnosis 1.0 [1.0–2.0]








Continuous variables are presented as median (interquartile range). Categorical variables are presented as number (percent-
age).
aSome patients used more than one antibiotic, therefore the percentage sum does not equal 100%.
CDI, Clostridioides difficile infection; ICU, intensive care unit.
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Figure 1 Most cases of CDI occurred inMarch and the least number of cases were found in January.
Full-size DOI: 10.7717/peerj.9972/fig-1
14.0 [4.0; 25.0]. Emergent procedures, prolonged stay in the intensive care unit, longer
mechanical ventilation and high WBC count during the diarrhea were associated with
higher mortality in patients with CDI (P = 0.05, P = 0.041, P = 0.004 and P = 0.007,
respectively), (Table 4).
DISCUSSION
The study showed that cardiac surgery related factors such as a type and timing of surgery,
aortic cross-clamp and cardiopulmonary bypass time, volume of postoperative drainage,
administration of blood products and value of postoperative ejection fraction were not
correlated with the risk of CDI.
Interestingly, in our study, patients with CDI had a lower level ofWBC count both before
and after surgery in comparison to the control group. It is known that WBC, especially
neutrophils, play an important role in the immune response against CD toxin A (Kelly et
al., 1994), therefore, patients with a low WBC count have a higher risk of acquiring CDI
(Gorschlüter et al., 2001). Unfortunately, in our study, neutrophil level was not determined,
only overall WBC count was analyzed.
In contrast to other studies, our results did not show that diabetes mellitus was a risk
factor for CDI (Furuya-Kanamori et al., 2015a). However, we did demonstrate that patients
with high glucose levels and stress hyperglycemia during the early postoperative period
were at greater risk for development of CDI. This finding is consistent with the results of
a study by Gelijns et al., who demonstrated the association of hyperglycemia with CDI
(Gelijns et al., 2014). Similarly, Kirkwood et al. showed that postoperative hyperglycemia
was associated with an increased risk of CDI (Kirkwood et al., 2018). Therefore, prevention
and treatment of hyperglycemia after cardiac surgery should be taken into consideration.
In our study, other risk factors for CDI were similar to those from non-cardiac surgery
reports (Belto, Litofsky & Humphries, 2019). Our findings confirm the results of many
studies that older age is an independent risk factor for CDI (McFarland, Surawicz & Stamm,
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BMI > 25 kg/m2, n(%) 41 (67.2) 9 (100.0) 0.052 43 (78.2) 7 (46.7) 0.025 (C)


















LVEF baseline< 40%, n(%) 13 (21.3) 1 (11.1) 0.675 9 (16.4) 5 (33.3) 0.161
Hospitalization < 6 month
before the surgery, n(%)
53 (86.9) 9 (100) 0.584 53 (96.4) 9 (60.0) 0.001 (C)
Comorbidities, n(%)
Atherosclerosis 30 (49.2) 3 (33.3) 0.485 29 (52.7) 4 (26.7) 0.133
Dyslipidemia 49 (80.3) 8 (88.9) 1.000 49 (89.1) 8 (53.3) 0.004
Coronary disease 40 (65.6) 9 (100.0) 0.049 (C) 41 (74.5) 8 (53.3) 0.125
Previous myocardial infarction 16 (26.2) 5 (55.6) 0.116 15 (27.3) 6 (40.0) 0.356
Atrial fibrillation 27 (44.3) 2 (22.2) 0.289 23 (41.8) 6 (40.0) 1.000
Diabetes mellitus 21 (34.4) 7 (77.8) 0.025 24 (43.6) 4 (26.7) 0.372
History of malignant neoplasms 9 (14.8) 0 (0.0) 0.592 8 (14.5) 1 (6.7) 0.672
Chronic kidney disease 19 (31.1) 1 (11.1) 0.430 17 (30.9) 3 (20.0) 0.528
Thyroid disease 14 (23.0) 2 (22.2) 1.000 13 (23.6) 3 (20.0) 1.000
Peptic ulcer disease 14 (23.0) 1 (11.1) 0.672 13 (23.6) 2 (13.3) 0.497
COPD 6 (9.8) 1 (11.1) 1.000 6 (10.9) 1 (6.7) 1.000
Medicines, n(%)
Statins 50 (82.0) 9 (100.0) 0.336 50 (90.9) 9 (60.0) 0.009
Acetylsalicylic acid 52 (85.2) 8 (88.9) 1.000 51 (92.7) 9 (60.0) 0.005
Beta blockers 51 (83.6) 9 (100.0) 0.339 48 (87.3) 12 (80.0) 0.437
ACE inhibitors 37 (60.7) 5 (55.6) 1.000 34 (61.8) 8 (53.3) 0.766
Insulin 15 (24.6) 3 (33.3) 0.685 15 (27.3) 3 (20.0) 0.744
PPI 53 (86.9) 8 (88.9) 1.000 49 (89.1) 12 (80.0) 0.392
Corticosteroids 4 (6.6) 0 (0.0) 1.000 3 (5.5) 1 (6.7) 1.000
Laboratory parameters









WBC baseline> 10,000 µL, n(%) 8 (13.1) 0 (0.0) 0.584 8 (14.5) 0 (0.0) 0.187









WBC postoperative> 13,000 µL, n(%) 17 (27.9) 4 (44.4) 0.437 16 (29.1) 5 (33.3) 0.758
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WBC during first CDI> 15,000, n(%) 26 (42.6) 3 (33.3) 0.726 19 (34.5) 10 (66.7) 0.025 (C)









Stress hyperglycemia postoperative, n(%) 40 (65.6) 8 (88.9) 0.255 37 (67.3) 11 (73.3) 0.761









CRP during first CDI> 60 mg/L, n(%) 26 (49.1) 9 (100.0) 0.004 (C) 28 (50.90) 7 (46.7) 0.742
Type of surgery, n(%) 0.716 0.955
CABG 22 (36.1) 3 (33.3) 20 (36.4) 5 (33.3)
VHS 25 (41.0) 4 (44.4) 22 (40.0) 7 (46.7)
CABG+VHS 6 (9.8) 1 (11.1) 6 (10.9) 1 (6.7)
Aortic surgery 6 (9.8) 0 (0.0) 5 (9.1) 1 (6.7)
CABG+aortic surgery 2 (3.3) 1 (11.1) 2 (3.6) 1 (6.7)
Reoperation, n(%) 5 (8.2) 0 (0.0) 1.000 3 (5.5) 2 (13.3) 0.290
Timing of surgery, n(%) 0.071 0.050 (C)
Elective 33 (54.1) 8 (88.9) 36 (65.5) 5 (33.3)
Emergent 28 (45.9) 1 (11.1) 19 (34.5) 10 (66.7)
Additional antibiotic, n(%) 45 (73.8) 1 (11.1) 0.001 36 (65.5) 10 (66.7) 1.000









LVEF after surgery< 30%, n(%) 5 (8.2) 0 (0.0) 1.000 3 (5.4) 2 (13.3) 0.290



























Postoperative drainage> 1,000 ml/first
24 h, n(%)
15 (24.6) 2 (22.2) 1.000 12 (21.8) 5 (33.3) 0.497
Inotropic agents, n(%) 42 (68.9) 6 (66.7) 1.000 37 (67.3) 11 (73.3) 0.761
IABP after surgery, n(%) 2 (3.3) 0 (0.0) 1.000 2 (3.6) 0 (0.0) 1.000
Accompanying infections, n(%)
Wound infection 11 (18.0) 2 (22.2) 0.670 9 (16.4) 4 (26.7) 0.455
VAC therapy 9 (14.8) 2 (22.2) 0.625 8 (14.5) 3 (20.0) 0.691
Positive blood cultures 9 (14.8) 1 (11.1) 1.000 4 (7.3) 6 (40.0) 0.005 (C)
Transfusion, n(%)
Red blood cells ≥2 units 39 (63.9) 4 (44.4) 0.292 33 (60.0) 10 (66.7) 0.864
Plasma ≥2 units 21 (34.4) 2 (22.2) 0.708 16 (29.1) 7 (46.7) 0.226
Platelets ≥1 unit 18 (29.5) 3 (33.3) 1.000 15 (27.3) 6 (40.0) 0.356
(continued on next page)











Times of the CDI diagnosis (days)


















Severity of CDI, n(%) 0.865 0.182
Non-severe 26 (42.6) 5 (55.6) 27 (49.1) 4 (26.7)
Severe 30 (49.2) 4 (44.4) 25 (45.5) 9 (60.0)
Fulminant 5 (8.2) 0 (0.0) 3 (5.5) 2 (13.3)
Notes.
Continuous variables are presented as median (interquartile range). Categorical variables are presented as number (percentage).
(C), Pearson’s chi-square test; (M), Mann–Whitney U test; ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; CDI,
Clostridioides difficile infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CRP, C-reactive protein; IABP, intra-aortic balloon pump;
LVEF, left ventricular ejection fraction; PPI, proton pump inhibitors; WBC, white blood cells; ICU, intensive care unit; VHS, valvular heart surgery; VAC, Vacuum-
assisted closure.
1990; De Roo & Regenbogen, 2020; Flagg et al., 2014; Belton, Litofsky & Humphries, 2019).
Unlike other reports, we did not find a correlation between female gender and development
of CDI (Flagg et al., 2014; Ge et al., 2018).
Some studies suggest an association between PPI and CDI risk whereas others do
not confirm this correlation (McFarland, Surawicz & Stamm, 1990; Eze et al., 2017;
Furuya-Kanamori et al., 2015a; Faleck et al., 2016; Maes, Fixen & Linnebur, 2017). The
exact mechanism of proliferation of CD in patients using PPI remains unclear (Maes, Fixen
& Linnebur, 2017). In our study, patients with CDI significantly more often used PPI. The
necessity of PPI use should be carefully evaluated for hospital patients, especially those
already receiving antibiotics.
Patients with CDI more frequently have chronic illnesses (Eze et al., 2017; De Roo &
Regenbogen, 2020; Furuya-Kanamori et al., 2015a; Kirkwood et al., 2018). In our study
atherosclerosis, ischemic heart disease and history of malignant neoplasms were correlated
with CDI. Furthermore, patients with CDI significantly more often received statins,
b-blockers and acetylsalicylic acid. This correlation could be explained by the fact that
these drugs are used to treat the comorbidities that are associated with development of
CDI. The correlation between EuroSCORE and CDI could be explained similarly.
Time of hospital stay is an important risk factor for the development of CDI (Flagg et
al., 2014; Chalmers et al., 2016). Spores can remain in the hospital environment for several
months and are difficult to remove with traditional disinfectants (Barbut, 2015). We also
showed the significant role of hospitalization time in the risk of CDI.
Besides periprocedural antimicrobial prophylaxis, some patients received an additional
antibiotic due to accompanying infections, and these patients had greater chance of
contracting CDI. In our study cefazolin, ceftriaxone and fluoroquinolone were the most
frequently used antibiotics (Table 3). The relationship between antibiotic treatment and
the risk of CDI has also been demonstrated in other studies (McFarland, Surawicz &
Stamm, 1990; Eze et al., 2017; De Roo & Regenbogen, 2020; Furuya-Kanamori et al., 2015a;
Kirkwood et al., 2018; Ge et al., 2018; Kazakova et al., 2020; Jachowicz et al., 2020). It should
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be remembered that any antibiotic may be the cause of CDI, even those used to treat CDI
(McDonald et al., 2018). Appropriate antibiotic management can help to reduce the risk of
postoperative CDI.
In this study, a large number of patients received metronidazole for CDI treatment
(Table 3). Our analysis was performed between 2014 and 2016 and treatment of CDI
was consistent with the 2010 recommendations (Cohen et al., 2010). Current guidelines
confirm that metronidazole has a lower efficacy compared with vancomycin and they
support the use of vancomycin over metronidazole in CDI (McDonald et al., 2018).
In our study the most cases of CDI occurred in March. This result is comparable with
other studies that have shown that CDI has a similar seasonal pattern characterized by a
peak in spring and lower frequencies in summer and autumnmonths (Furuya-Kanamori et
al., 2015b). Jachowicz et al. (2020) showed an additional peak of healthcare associated CDI
occurring from October to December. The mechanisms responsible for the seasonality of
CDI remain poorly understood, although it has been proposed that the observed seasonality
is associated with a higher incidence of respiratory infections, which leads to an intensified
use of antibiotics during winter and spring months.
One of the most challenging aspects for patients with CDI is the recurrence of the disease
after successful initial therapy is completed, which has been observed in between 15 to 35%
of patients (De Roo & Regenbogen, 2020; Dharbhamulla et al., 2019). We observed a relapse
in about 13% of patients with CDI. It is possible that this discrepancy was the result of
different times of observation. In our study we assessed relapses that occurred only during
the same hospitalization stay as the surgery. The causes of recurrent CDI are also unclear
(Dharbhamulla et al., 2019). In our study, the risk of recurrent CDI significantly increased
for patients with diabetes mellitus or ischemic heart disease and for those with higher BMI
or higher glucose level on the day of surgery. Similar to Predrag et al., we also revealed an
association of relapses with high CRP during the first episode of CDI (Predrag et al., 2020).
Data on mortality for patients who acquired CDI after surgery varies from 2.5 to 27.7%
and is much higher than mean in-hospital death after cardiac surgery (1–4%) (Vondran et
al., 2018; Flagg et al., 2014;Mazzeffi et al., 2014). Our result of a 21%mortality rate validate
these findings. We showed that patients that had emergent procedures, prolonged stay
in the intensive care unit, longer mechanical ventilation or a high WBC count during
an episode of diarrhea have a higher risk of death. These findings are consistent with
other results (Ricciardi et al., 2007; Furuya-Kanamori et al., 2015a; Furuya-Kanamori et al.,
2015b; Gelijns et al., 2014; Vondran et al., 2018; Flagg et al., 2014; Debast, Bauer & Kuijper,
2014). In our study, prolonged hospitalization time before surgery was a risk factor for CDI
but correlated with lower mortality. Longer hospital stay could help to ensure that patients
enter elective surgery in the best condition possible in contrast to emergent procedures.
Limitations
This study has several limitations. It was a retrospective study based on available data
obtained during patients’ cardiac procedure hospital stay. Therefore, the true incidence
of CDI could be higher due to a lack of information regarding potential post-discharge
diagnosis of the disease. The size of the study group was limited and patients were very
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heterogeneous. It is probable that analysis of patients with one type of cardiac surgery may
provide different results.
CONCLUSION
In conclusion, this study did not reveal any specific cardiac surgery-related risk factors
for development of CDI. Also, frequency of relapse and mortality rate were similar to
non-cardiac surgery. Studies in larger cohorts are needed to confirm these findings.
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